Company Overview and News

 
Nikkei rises as easing U.S.-China trade tensions support dollar, exporters

8h reuters
TOKYO, May 21 (Reuters) - Japan’s Nikkei share average rose on Monday as the dollars’ rise against the yen supported some exporters after news of easing U.S.-China trade tensions, but weakness in financial stocks kept wider gains limited.

 
Nikkei rises as U.S.-China trade tensions put "on hold"

12h reuters
TOKYO, May 21 (Reuters) - Japan’s Nikkei share average rose on Monday morning as exporters were boosted by a rise in the dollar rise against the yen.

 
This $2 Billion AI Startup Aims to Teach Factory Robots to Think - Bloomberg

2018-05-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
IBM selects Keio to host first quantum computing hub in Asia

2018-05-17 japantimes.co.jp
Keio University opened a research hub Thursday that can access IBM Corp.’s cutting-edge quantum computer system through the internet, with the aim of studying the possibilities of harnessing quantum computing.

 
Sumitomo Mitsui Signals It May Curb Coal-Fired Power Financing - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
MFG / Mizuho Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-15 sec.gov
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
MFG / Mizuho Financial Group Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-15 sec.gov
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Regional banks fight for inheritance to ensure their survival

2018-05-15 japantimes.co.jp
Where there’s a will, there’s a way. That’s what banks across Japan are counting on as they try to keep hold of the ¥50 trillion in wealth left by their customers each year when they die.

 
Nikkei drops in choppy trade; Toshiba up on chip unit sale

2018-05-15 reuters
TOKYO, May 15 (Reuters) - Japanese stocks pulled back from a recent 3-1/2 month high on Tuesday, hit by profit-taking, though bank shares staged a rally on hopes of strong earnings for the sector.

 
Nikkei eases in choppy trade; banks rise on earnings hopes

2018-05-15 thehindubusinessline
Japanese stocks pulled back from 3-1-/2-month highs on Tuesday morning, though bank shares staged a rally on hopes of strong earnings for the sector.

 
Nikkei eases in choppy trade; banks rise on earnings hopes

2018-05-15 reuters
TOKYO, May 15 (Reuters) - Japanese stocks pulled back from 3-1-/2-month highs on Tuesday morning, though bank shares staged a rally on hopes of strong earnings for the sector.

 
Japan’s Banks Want to Keep Hold of Dead Customers’ Savings - Bloomberg

2018-05-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Asia markets: Oil, stocks, currencies and China data in focus

2018-05-15 cnbc
Asian shares looked set for a mixed start on Tuesday after U.S. stock indexes recorded gains amid an improvement in sentiment over U.S.-China trade developments.

 
Total net profit at Japan’s three mega-bank groups likely to grow for first time in four years

2018-05-08 japantimes.co.jp
The total net profit for Japan’s three mega-bank groups are believed to have grown year on year for the first time in four years in the fiscal year that ended in March.

 
Nikkei rises as banks rally; Takeda up ahead of acquisition news

2018-05-08 reuters
TOKYO, May 8 (Reuters) - Japan’s Nikkei share average rose on Tuesday as banking stocks rallied while Takeda Pharmaceutical climbed ahead of news the drugmaker had agreed to buy London-listed Shire for $62.42 billion.

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

8h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

CUSIP: 60687Y109